Acquired by Proove Biosciences in May 2016, Algynomics Inc is focused on development of personalized pain therapies and new pharmacological treatments for chronic pain conditions. The Algynomics platform and its patient cohorts provide researchers with prospective data to identify individuals at increased risk for the development of chronic pain, allowing targeted preventive efforts, enhanced patient stratification in clinical trials to identify treatment responders, produce more sensitive inclusion/exclusion criteria for trial enrollment, and development of algorithms to tailor treatment for pain, enhancing outcomes and reducing adverse effects. Algynomics developed the Translational Pain Genetics Consortium (TPGC) to improve the effectiveness and efficiency of applied and fundamental pain research through exclusive availability of cross-validated unique cohorts of pain patient supported by Algynomics experience, expertise and state of the art analytical tools.
